ATE500273T1 - Methoden zur analyse von antikörperdisulfidisomere - Google Patents

Methoden zur analyse von antikörperdisulfidisomere

Info

Publication number
ATE500273T1
ATE500273T1 AT03745158T AT03745158T ATE500273T1 AT E500273 T1 ATE500273 T1 AT E500273T1 AT 03745158 T AT03745158 T AT 03745158T AT 03745158 T AT03745158 T AT 03745158T AT E500273 T1 ATE500273 T1 AT E500273T1
Authority
AT
Austria
Prior art keywords
isomers
methods
antibody
tnfalpha
relates
Prior art date
Application number
AT03745158T
Other languages
German (de)
English (en)
Inventor
Ned Mozier
Robert Dufield
Jianming Mo
Gary Bild
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE500273T1 publication Critical patent/ATE500273T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
AT03745158T 2002-03-20 2003-03-20 Methoden zur analyse von antikörperdisulfidisomere ATE500273T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635002P 2002-03-20 2002-03-20
PCT/US2003/008608 WO2003080674A1 (en) 2002-03-20 2003-03-20 Antibody disulfide isomers, use thereof, and methods of analyzing same

Publications (1)

Publication Number Publication Date
ATE500273T1 true ATE500273T1 (de) 2011-03-15

Family

ID=28454787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03745158T ATE500273T1 (de) 2002-03-20 2003-03-20 Methoden zur analyse von antikörperdisulfidisomere

Country Status (10)

Country Link
US (1) US20060171940A1 (https=)
EP (1) EP1495056B1 (https=)
JP (2) JP4441269B2 (https=)
AT (1) ATE500273T1 (https=)
AU (1) AU2003225900A1 (https=)
DE (1) DE60336214D1 (https=)
DK (1) DK1495056T3 (https=)
ES (1) ES2358505T3 (https=)
PT (1) PT1495056E (https=)
WO (1) WO2003080674A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
CN102471375A (zh) * 2009-07-09 2012-05-23 F-斯塔生物技术研究和发展有限公司 稳定的免疫球蛋白恒定结构域
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
CN119861168B (zh) * 2024-12-30 2025-09-23 浙江大学 一种识别β-内酰胺类抗生素中二聚物异构体的智能分析系统及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) * 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2003099226A2 (en) * 2002-05-28 2003-12-04 Celltech R & D Limited Antibody peg positional isomers, compositions comprising same, and use thereof

Also Published As

Publication number Publication date
EP1495056A1 (en) 2005-01-12
JP2009153528A (ja) 2009-07-16
JP5352761B2 (ja) 2013-11-27
WO2003080674A1 (en) 2003-10-02
AU2003225900A1 (en) 2003-10-08
ES2358505T3 (es) 2011-05-11
EP1495056A4 (en) 2005-09-28
DK1495056T3 (da) 2011-05-02
US20060171940A1 (en) 2006-08-03
PT1495056E (pt) 2011-03-29
JP2006505497A (ja) 2006-02-16
JP4441269B2 (ja) 2010-03-31
EP1495056B1 (en) 2011-03-02
DE60336214D1 (de) 2011-04-14

Similar Documents

Publication Publication Date Title
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
EA201001528A1 (ru) Антитела к склеростину и способы их применения
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
DE69800716D1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
EP1442295A4 (en) DIAGNOSTIC TESTS ON PERIESTINE BASIS
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE334391T1 (de) Isolierung und analyse von proteinen
EP2147928A3 (en) Peptide-based immunization therapy for treatment of atherosclerososis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
ATE488530T1 (de) Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
EA200601545A1 (ru) АНТИ-Aβ АНТИТЕЛА
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
PT1639011E (pt) Anticorpos (dab) de domínio único peguilados
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
EA019476B9 (ru) АНТИТЕЛА ПРОТИВ IL-23p19 И ИХ ПРИМЕНЕНИЕ
MX2024009860A (es) Anticuerpos monoclonales humanos que se dirigen ampliamente a los coronavirus
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
WO2022020234A3 (en) Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
EA200401628A1 (ru) Ингибиторы пептидной деформилазы
ATE551355T1 (de) Zusammensetzungen und verfahren zur erkennung von antikörpern gegen ehrlichia canis und ehrlichia chaffeensis
ATE500273T1 (de) Methoden zur analyse von antikörperdisulfidisomere
ATE347561T1 (de) Behandlung von entzündungskrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1495056

Country of ref document: EP